Sowell Financial Services LLC Makes New Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Sowell Financial Services LLC bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,262 shares of the specialty pharmaceutical company's stock, valued at approximately $352,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. US Bancorp DE boosted its stake in ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after acquiring an additional 531 shares during the last quarter. GAMMA Investing LLC increased its stake in ANI Pharmaceuticals by 163.8% during the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after buying an additional 881 shares during the period. KLP Kapitalforvaltning AS acquired a new position in ANI Pharmaceuticals during the 4th quarter valued at about $166,000. Rafferty Asset Management LLC bought a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at about $200,000. Finally, Bridgefront Capital LLC bought a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at about $204,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 4,000 shares of the company's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total transaction of $241,800.00. Following the completion of the transaction, the insider now owns 107,317 shares of the company's stock, valued at $6,487,312.65. This represents a 3.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Meredith Cook sold 400 shares of the company's stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $68.96, for a total value of $27,584.00. Following the transaction, the vice president now directly owns 80,145 shares of the company's stock, valued at approximately $5,526,799.20. This trade represents a 0.50% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 5,681 shares of company stock worth $346,854. 11.10% of the stock is owned by company insiders.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $65.56 on Friday. The company has a debt-to-equity ratio of 1.46, a current ratio of 2.66 and a quick ratio of 1.98. The stock has a market cap of $1.42 billion, a PE ratio of -51.62 and a beta of 0.55. The stock has a 50-day moving average of $64.62 and a 200-day moving average of $61.30. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. The company had revenue of $197.12 million during the quarter, compared to analysts' expectations of $179.75 million. During the same period in the prior year, the business posted $0.82 EPS. ANI Pharmaceuticals's revenue was up 43.4% on a year-over-year basis. As a group, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Analyst Ratings Changes

ANIP has been the topic of several recent research reports. Truist Financial raised their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research report on Monday, April 21st. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. Guggenheim reiterated a "buy" rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price on the stock. Finally, Jefferies Financial Group began coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 price target for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $80.13.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.